1. Home
  2. Browse Decisions
  3. A.D.3d
  4. 212 A.D.3d
  5. 212 A.D.3d 96 (2022)
 

SCHWARTZ v. GENFIT, S.A.

Index No. 657123/20 Appeal No. 16575-16575A Case No. 2021-04513.

212 A.D.3d 96 (2022)

180 N.Y.S.3d 100

2022 NY Slip Op 06892

DARYL SCHWARTZ, Appellant, v. GENFIT, S.A., et al., Respondents.

Appellate Division of the Supreme Court of New York, First Department.

Decided December 6, 2022.

Attorney(s) appearing for the Case

Pomerantz LLP, New York City (Michael J. Wernke and Jeremy A. Lieberman of counsel), Pomerantz, LLP, Chicago, IL (Patrick V. Dahlstrom, of counsel), and Bronstein, Gewirtz & Grossman, LLC, New York City (Peretz Bronstein of counsel), for appellant.

Cooley LLP, New York City (Sarah M. Lightdale, Aric H. Wu, and Christopher L. Martin, Jr. of counsel), for Genfit, S.A. and others, respondents.

Skadden, Arps, Slate, Meagher & Flom LLP, New York City (Susan L. Saltzstein, Scott D. Musoff and Maria da Silva of counsel), for SVB Leerink LLC and others, respondents.

GESMER, OING, KENNEDY and SCARPULLA, JJ. concur.

OPINION OF THE COURT

Defendant Genfit, S.A. is a French pharmaceutical company. Its main product is a drug called elafibranor, which Genfit hoped would treat a liver disease known as nonalcoholic steatohepatitis (NASH). In order to obtain FDA approval, Genfit conducted clinical trials to determine the drug's efficacy. After...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases